MAY 30, 2018 05:21 AM PDT

Non-Diet Therapy For PKU

WRITTEN BY: Nouran Amin

Phenylketonuria (PKU) is a rare inherited disorder that results an amino acid known as phenylalanine to build up in the body.

 

PKU is caused by a mutation in the gene responsible for producing the enzyme needed to break down phenylalanine. Without the enzyme, a toxic buildup can develop for individuals with PKU when they ingest foods that contain protein or aspartame; eventually leading to serious health complications. Babies born in the United States and many other countries are screened for PKU after birth, in order to recognize it right away and avoid any major health problems. For the rest of their lives, individuals with PKU — babies, children, and adults — must follow a strict diet that is phenylalanine-free.

Until this most recently, one of the only non-diet treatment options for individuals of PKU consisted of replacement cofactor; BioMarin’s Kuvan (sapropterin dihydrochloride). Kuvan binds to and enhances the activity of phenylalanine hydroxylase (PAH), an enzyme that metabolizes phenylalanine. “While Kuvan has been helpful to some people, it doesn't really benefit the large portion of our community, and many of those people are still struggling,” states Christine Brown, executive director of the National PKU Alliance (NPKUA), a nonprofit patient advocacy group, and the mother of two boys with PKU, “For most people, even on Kuvan, they still have to take medical foods.” Now, the FDA has recently approved another non-diet therapy: an enzyme substitute known as pegvaliase (Palynziq).

Palynziq metabolizes phenylalanine, replacing the deficient PAH enzyme that in PKU patients. “It is great that the FDA has approved . . . [Palynziq],” writes Francjan van Spronsen, a pediatrician specializing in inherited metabolic diseases at the University of Groningen in the Netherlands. “We have heard very promising results [that patients’] whole lives have changed, as now at least some of them can do without [specialized] diets or have increased their phenylalanine tolerance to a large degree.” As of now, Palynziq is only approved for use in the U.S and only for adult patients with uncontrolled phenylalanine amounts. Palynziq also comes with a black box warning due to the risk of anaphylaxis, which is severe and may be fatal allergic reaction if not treated. BioMarin has stated has announced that the therapy is expected to cost approximately $192,000 per year.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
NOV 05, 2018
Drug Discovery
NOV 05, 2018
Drug Combination Halts The Progression of Fibrosis
After seven years of research, scientists at Anglia Ruskin University, University College London and KU Leuven—developed a drug combination that hold...
NOV 05, 2018
Microbiology
NOV 05, 2018
Potential Antidote to Botulism is Found
A microbe called Clostridium botulinum and sometimes two other strains of Clostridium bacteria can make a toxic chemical called botulism....
DEC 19, 2018
Drug Discovery
DEC 19, 2018
Promising Drug for ALS?
ALS, standing for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease affecting the nerve cel...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Type 2 Diabetes Drug May Treat Heart Failure Syndrome
A drug used in the treatment of Type 2 Diabetes, by the name of Metformin, may soon be used to treat heart failure syndrome with preserved ejection fractio...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
Loading Comments...